Krzysztof Warzocha
Warsaw, MZ 00791, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.
Journal: Cancers
Published: December 21, 2021
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 11, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 20, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
Journal: Journal of hematology & oncology
Published: April 20, 2021
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
Journal: Future oncology (London, England)
Published: February 02, 2021
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Journal: Leukemia research
Published: October 30, 2020
Performance of Maraging Steel Sleeves Produced by SLM with Subsequent Age Hardening.
Journal: Materials (Basel, Switzerland)
Published: July 05, 2020
IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.
Journal: Scientific reports
Published: March 02, 2020
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Journal: The Lancet. Haematology
Published: February 12, 2020
Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group.
Journal: Advances in medical sciences
Published: January 21, 2020
Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
Journal: Cardiovascular toxicology
Published: December 03, 2019
Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium.
Journal: Leukemia & lymphoma
Published: November 21, 2019
Last Updated: 09/26/2026